have found the correlation between TP53 mutations and GC liver metastasis by next-generation sequencing, and the rate of TP53 mutations was significantly higher in advanced GC patients with liver metastasis compared to those without liver metastasis (86.5% vs. 40.5%), although the exact mechanism of TP53 mutations on liver metastasis needs to be further investigated (43). The gene discussed is TP53; the disease is gastric cancer.